Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paperTong‐Yuan Yang, Vibha Jawa, Lena Hofer et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 113
2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccine Assays; Immunogenicity of Biotherapeutics and Novel Modalities; Integrated Summary of Immunogenicity Harmonization)LiNa Loo, Robert Kubiak, Shannon Harris et al.|Bioanalysis|2022Cited by 35
PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position PaperUma Kavita, Nagendra Chemuturi, Kefeng Sun et al.|The AAPS Journal|2023Cited by 17
2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( <u>Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)Luying Pan, Swati Gupta, Johanna Mora et al.|Bioanalysis|2023Cited by 15